By inhibiting the binding of angiotensin II to AT1R, it is hypothesised that ARBs may reduce the inflammatory effects of SARS-CoV-2 infection, thereby reducing the risk of severe COVID-19. The gene discussed is AGTR1; the disease is COVID-19.